INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.

Larimar Therapeutics (LRMR) faces an investor investigation by Pomerantz LLP into potential securities fraud/unlawful practices tied to nomlabofusp safety disclosures. Following the Sept. 29, 2025 update, shares fell 33.66% ($1.72) to $3.38 after anaphylaxis/severe allergic reactions were reported in 7 participants, and on June 29, 2026 shares fell another 12.57% ($0.46) to $3.20 despite a rolling BLA submission, with anaphylaxis reported in 10 of 43 patients.

Analysis

This is less a stand-alone litigation headline than a financing and regulatory risk premium reset. In rare-disease biotech, repeated severe hypersensitivity events usually matter more for the equity than the lawsuit itself because they raise the odds of a restrictive label, REMS-like monitoring burden, slower physician adoption, and a higher cost of capital right when the company may need fresh funding. That combination tends to compress valuation well before any legal outcome is known.

The immediate loser is LRMR; the second-order winner is the incumbent standard-of-care ecosystem, especially BIIB, because prescribers facing a safety question will default toward the therapy with the cleaner commercial and post-marketing profile. Broader small-cap biotech, proxied by XBI, can also feel spillover if investors extrapolate that accelerating BLA timelines do not rescue names with unresolved safety signals. If the safety issue forces protocol changes, the true downside is not just revenue delay but a step-up in trial complexity and slower label expansion for the whole franchise.

The market may be underpricing how binary the next 1-3 months are: acceptance of the rolling BLA does not equal approvability, and the key falsifier is any FDA request for additional safety data, a clinical hold, or a materially restricted label. Conversely, if management can show the event rate plateaus and no new severe hypersensitivity emerges, the legal overhang should fade faster than the fundamental one. My base case is that the stock remains a trading vehicle around headlines rather than a clean long until regulatory clarity improves.

Key Decisions for Investors

• Short LRMR on any post-headline bounce; use a 4-12 week horizon and cover if FDA/BLA updates explicitly remove the hypersensitivity overhang or if the company discloses no new severe events across the next dataset.
• Prefer a pair trade: long BIIB / short LRMR for the next 1-3 months to express flight-to-quality within Friedreich’s ataxia, where physician behavior should favor the safer incumbent if uncertainty persists.
• If options liquidity allows, buy LRMR put spreads 1-2 months out rather than outright puts; the catalyst is incremental negative disclosure, but the name can gap on binary news and spreads reduce theta bleed.
• Avoid chasing short-biotech ETFs solely on this item; use XBI only as a hedge against sector-wide risk-off if you expect the LRMR issue to drag multiple pre-commercial names lower.
• Watch for a regulatory falsifier: BLA acceptance with no information request, absence of a hold, and any management commentary that the hypersensitivity events are manageable without dose restriction would argue for taking profits on tactical shorts.